ES2087964T3 - Contraceptivos orales bajos en estrogenos. - Google Patents

Contraceptivos orales bajos en estrogenos.

Info

Publication number
ES2087964T3
ES2087964T3 ES91203182T ES91203182T ES2087964T3 ES 2087964 T3 ES2087964 T3 ES 2087964T3 ES 91203182 T ES91203182 T ES 91203182T ES 91203182 T ES91203182 T ES 91203182T ES 2087964 T3 ES2087964 T3 ES 2087964T3
Authority
ES
Spain
Prior art keywords
dosage units
equivalent
desogestrel
phase
progestogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91203182T
Other languages
English (en)
Inventor
Engelbert Wilhelm Bergink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2087964(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2087964T3 publication Critical patent/ES2087964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

SE DESCRIBE UN REGIMEN ANTICONCEPTIVO, Y UN METODO DE UTILIZACION DEL REGIMEN, QUE CONSTA DE 24 UNIDADES DE DOSIFICACION DE SECUENCIA DIARIA DE : UNA PRIMERA FASE QUE INCLUYE APROXIMADAMENTE ENTRE 7 Y 9 PRIMERAS UNIDADES DE DOSIFICACION QUE CONTIENEN UN PROGESTOGENO EN UNA DOSIS DIARIA EQUIVALENTE EN ACTIVIDAD PROGESTOGENICA A 100 (MU)G DE DESOGESTREL Y UN ESTROGENO EN UNADOSIS DIARIA EQUIVALENTE EN ACTIVIDAD ESTROGENICA A 25 (MU)G DE ETININIL ESTRADIOL ("EE"). UNA SEGUNDA FASE DE 7 A 9 SEGUNDAS UNIDADES DE DOSIFICACION, CADA UNA DE LAS SEGUNDAS UNIDADES DE DOSIFICACION CONTIENE UN PROGESTOGENO EQUIVALENTE A 125 (MU)G DE DESOGESTREL Y UN ESTROGENO EQUIVALENTE A 20 (MU)G DE EE. UNA TERCERA FASE DE 7 A 9 TERCERAS UNIDADES DE DOSIFICACION, CADA UNIDAD CONTIENE UN PROGESTOGENO EQUIVALENTE A 150 (MU)G DESOGESTREL Y UN ESTROGENO EQUIVALENTE A 20 (MU)G DE EE. EL CONJUNTO TIENE GENERALMENTE 28 UNIDADES DE DOSIFICACION DIARIAS DE LAS QUE CUATRO DE LAS UNIDADES DE DOSIFICACION DIARIAS NO CONTIENEN ESTEROIDES ANTICONCEPTIVOS, O, COMO ALTERNATIVA, TIENE SOLO 24 UNIDADES DE DOSIFICACION CON UN PERIODO DE CUATRO DIAS "LIBRE DE PILDORAS". LA CUARTA FASE PUEDEN SER TAMBIEN CUATRO UNIDADES DE DOSIFICACION QUE CONTENGAN UN PROGESTOGENO EQUIVALENTE A 25-35 (MU)G DE DESOGESTREL.
ES91203182T 1990-12-13 1991-12-05 Contraceptivos orales bajos en estrogenos. Expired - Lifetime ES2087964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203309 1990-12-13

Publications (1)

Publication Number Publication Date
ES2087964T3 true ES2087964T3 (es) 1996-08-01

Family

ID=8205195

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91203182T Expired - Lifetime ES2087964T3 (es) 1990-12-13 1991-12-05 Contraceptivos orales bajos en estrogenos.

Country Status (18)

Country Link
US (1) US5262408A (es)
EP (1) EP0491415B1 (es)
JP (1) JPH04290828A (es)
KR (1) KR100187316B1 (es)
CN (1) CN1036835C (es)
AT (1) ATE136218T1 (es)
AU (1) AU645382B2 (es)
CA (1) CA2057528C (es)
DE (1) DE69118493T2 (es)
DK (1) DK0491415T3 (es)
ES (1) ES2087964T3 (es)
FI (1) FI99083C (es)
GR (1) GR3020179T3 (es)
IE (1) IE71203B1 (es)
NO (1) NO179234C (es)
NZ (1) NZ240944A (es)
PT (1) PT99782B (es)
ZA (1) ZA919731B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) * 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
EP0917466B1 (en) * 1996-07-26 2004-10-06 Wyeth Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
AU3888697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Progestin/estrogen oral contraceptive
KR100518102B1 (ko) * 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
HU230759B1 (hu) * 2001-12-05 2018-03-28 Teva Women's Health, Inc. Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények
US20030225048A1 (en) * 2002-03-11 2003-12-04 Caubel Patrick Michel Sulfatase inhibiting continuous progestogen contraceptive regimens
TW200403075A (en) * 2002-05-29 2004-03-01 Akzo Nobel Nv Progestagenic dosage units
JP2004140323A (ja) * 2002-08-20 2004-05-13 Sharp Corp 半導体レーザ装置およびその製造方法
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
US20040259851A1 (en) * 2003-04-11 2004-12-23 Leonard Thomas W. Methods of administering estrogens and progestins
SI1820494T1 (sl) * 2003-06-13 2010-08-31 Skendi Finance Ltd Mikrodelci, ki sestojijo iz estradiola in holesterola
EP1648382A4 (en) * 2003-07-16 2009-09-16 Duramed Pharmaceuticals Inc HORMONE TREATMENT METHODS USING CONTRACEPTIVE DOSAGES WITH CONTINUOUS ADMINISTRATION OF ESTROGENES
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20060135496A1 (en) * 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431704A1 (de) * 1974-07-02 1976-01-22 Asche Ag Stufenkombinationspraeparate per kontrazeption
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet

Also Published As

Publication number Publication date
FI99083C (fi) 1997-10-10
AU645382B2 (en) 1994-01-13
AU8964791A (en) 1992-06-18
CA2057528C (en) 2003-02-04
EP0491415A1 (en) 1992-06-24
JPH04290828A (ja) 1992-10-15
US5262408A (en) 1993-11-16
NO914900L (no) 1992-06-15
IE71203B1 (en) 1997-02-12
CN1036835C (zh) 1997-12-31
DE69118493D1 (de) 1996-05-09
NZ240944A (en) 1994-05-26
NO179234C (no) 1996-09-04
DK0491415T3 (da) 1996-07-08
NO179234B (no) 1996-05-28
KR100187316B1 (ko) 1999-05-01
FI915855A0 (fi) 1991-12-12
ATE136218T1 (de) 1996-04-15
CA2057528A1 (en) 1992-06-14
IE914221A1 (en) 1992-06-17
KR920011517A (ko) 1992-07-24
CN1062290A (zh) 1992-07-01
PT99782B (pt) 2001-05-31
GR3020179T3 (en) 1996-09-30
FI99083B (fi) 1997-06-30
FI915855A (fi) 1992-06-14
ZA919731B (en) 1992-09-30
EP0491415B1 (en) 1996-04-03
NO914900D0 (no) 1991-12-12
DE69118493T2 (de) 1996-08-22
PT99782A (pt) 1992-12-31

Similar Documents

Publication Publication Date Title
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
FI915914A0 (fi) Ehkäisyvalmiste
RU96115196A (ru) Состав для контрацепции
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
CA2356747A1 (en) Triphasic oral contraceptive
NZ332894A (en) A regimen containing progestogen and/or estrogen with two or more anti-progestogen dosage units
NZ333862A (en) Triphasic oral contraceptive method and kit comprising a combination of progestin and estrogen
WO1997006807A3 (de) Kombinationspräparat zur kontrazeption, kits diese enthaltend und eine methode diese verwendend
ATE249222T1 (de) Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
GB1475790A (en) Contraceptive method and pack
Hall Once-a-month injectable contraceptives
RU98114084A (ru) Способ и набор для контрацепции женских особей млекопитающих, состоящий из комбинации гестагена и эстрогена

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 491415

Country of ref document: ES